GHRP-6What the studies show
The 1984 hexapeptide that came before its own receptor and before ghrelin — and the reason the hunger it causes is the receptor doing its job.
5 min read · Small human studies · Updated November 2026
In short
- Name
- GHRP-6
- Evidence
- Small human studies
- Bottom line
- Rat pituitary work and single-dose hormone studies in healthy men from the 1980s and 1990s, plus the receptor and ghrelin discoveries it enabled; strong evidence that it releases growth hormone, and no trial of any outcome a person would feel.
Before you read this
This guide explains what published studies found. That is all it is.
It is not medical advice and it is not instructions for using anything. Where a dose appears, we are reporting what a named study gave the people or animals in it — a fact about the study, not an instruction to you.
The compounds here are not approved by the FDA for use in people and are sold for laboratory research only. A study tells you what happened to the subjects in it; it does not tell you what would happen to you. Talk to a doctor first.
What it is
GHRP-6 is a chain of six amino acids, two of them in the D form, made in the early 1980s by Cyril Bowers and Frank Momany at Tulane University. They were not copying a natural hormone. They started from opioid-peptide fragments that happened to release a little growth hormone and reworked them until they had a molecule that released it strongly; the 1984 paper in Endocrinology showed it acting on rat pituitary cells and in live animals through a route that was not the GHRH receptor 1. The receptor it does use was not identified until 1996 2, and the body's own hormone for that receptor, ghrelin, was not discovered until 1999 3. The drug came first, then the receptor, then the hormone, which is the reverse of the usual order and the main reason GHRP-6 matters to the history of this field.
The rest of this guide is free
Unlock the GHRP-6 guide — and every other one
What the studies found, what they didn't, every source linked. Enter your email once; the link we send opens all of them on this device, plus one plain-language study breakdown a week.
In people
The key human study is from 1990. Bowers' group gave GHRP-6 by vein to healthy men and measured a clear growth hormone peak; given together with GHRH, the peak was larger than the sum of the two separate responses, a synergy that has shaped how this whole class is thought about since 4. The study was a single-dose hormone measurement in a small number of men. It did not measure muscle, fat, strength or anything a person would notice.
GHRP-6 is not a clean signal. In the 1998 paper that introduced ipamorelin, GHRP-6 and GHRP-2 raised ACTH and cortisol in pigs alongside growth hormone, and the newer peptide was designed specifically to avoid that 5. GHRP-6 is not an approved drug in any country.
The receptor it revealed
In 1996 a Merck group used GHRP-6 and a related non-peptide to fish out the receptor they bind: a G-protein-coupled receptor found in the pituitary and, separately, in the hypothalamus 2. Three years later Kojima and colleagues in Japan found the natural ligand for that orphan receptor in an unexpected place, the stomach, and named it ghrelin 3. So GHRP-6 is best understood as a synthetic stand-in for ghrelin, and whatever ghrelin's receptor does, GHRP-6 does. That order of discovery is called reverse pharmacology, and GHRP-6 is its textbook case: a synthetic molecule used as the probe to find a receptor, which in turn led to a hormone no one knew existed.
Why it makes animals hungry
Ghrelin's receptor is in the hypothalamus, the part of the brain that governs appetite, not only in the pituitary 2. A 1995 study delivered GHRP-6 directly into the brain ventricles of rats and found that they ate more, and that the extra eating happened without any change in the growth hormone response, which separated the two effects 6. In other words, hunger after GHRP-6 is not a side effect in the usual sense; it is the second half of what the receptor is for. Among the GHRPs it is the trait GHRP-6 is most associated with.
What is not known
GHRP-6 is four decades old and the human literature is almost entirely acute hormone measurements. There is no placebo-controlled trial of GHRP-6 for body composition, performance, sleep or recovery in people, and no published data on what repeated use over months does to the growth hormone response, to appetite, or to cortisol. Nor has the hunger effect been measured in a controlled human study with GHRP-6 itself; the direct human measurement for this class was made with GHRP-2. The clinical path for this class went through its successors; GHRP-6 itself stayed a research tool.
What these studies are, and aren't
Small human studies. Rat pituitary work and single-dose hormone studies in healthy men from the 1980s and 1990s, plus the receptor and ghrelin discoveries it enabled; strong evidence that it releases growth hormone, and no trial of any outcome a person would feel.
Sources
- 1Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 1984.
- 2Howard AD et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 1996.
- 3Kojima M et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999.
- 4Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 1990.
- 5Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- 6Locke W, Kirgis HD, Bowers CY, Abdoh AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sciences, 1995.
More in Growth hormone axis
- CJC-1295 (no DAC): What the Studies ShowSermorelin with four amino acids swapped to survive the blood longer, and without the albumin-binding tail that gave the DAC version its week-long half-life.
- CJC-1295 + Ipamorelin: What the Studies ShowTwo peptides for two receptors on the same pituitary cell. The idea comes from a 1990 study in men; the pair itself has never been tested together.
- CJC-1295 with DAC: What the Studies ShowA GHRH analogue that bonds to albumin in the blood: one injection raised growth hormone for about a week in healthy adults, with the normal pulses intact.
- GHRP-2: What the Studies ShowThe potent GHRP approved in Japan as a one-dose test for growth hormone deficiency, and shown to make healthy men eat about a third more at a single meal.
- Hexarelin: What the Studies ShowGHRP-6 with one methyl group added, active by mouth and nose as well as by injection, and the GHRP whose growth hormone response was shown to fade by 16 weeks.